2 results
Approved WMORecruiting
To compare the therapeutic benefit of maintenance pazopanib versus placebo after first line treatment of NSCLC.
Approved WMOCompleted
Primary: The primary objective is to determine whether treatment with alpelisib in combination with fulvestrant prolongs progression free survival (PFS) compared to treatment with placebo in combination with fulvestrant based on local radiological…